MAP2K7 and melanoma: ,5 More than 90% of all clinically recorded BRAF-mutated melanomas carry a V600E mutation,6,7 which can be targeted pharmacologically by inhibition of BRAF itself or the downstream kinase MEK with drugs like dabrafenib and trametinib, respectively.